Transfusion最新文献

{"title":"Clot formation and resolution properties of platelets during cold storage for 21 days.","authors":"Janhavi Mahajan, Matthew P Padula, Denese C Marks, Lacey Johnson","doi":"10.1111/trf.18283","DOIUrl":"https://doi.org/10.1111/trf.18283","url":null,"abstract":"<p><strong>Background: </strong>Cold storage (2-6°C) preserves the aggregatory and clot formation properties of platelets beyond the standard 7-day shelf life. Comparatively little is known about the effect of cold storage on clot resolution functions, which are necessary to ensure normal hemostatic balance is maintained.</p><p><strong>Study design and methods: </strong>Double-dose apheresis platelets (n = 8) were collected using the Trima apheresis platform (40% plasma/60% PAS-E). Platelets were sampled on Day 1 post-collection and allocated to room temperature (RT; 20-24°C) or cold storage (2-6°C). In vitro testing was performed over a 21-day period.</p><p><strong>Results: </strong>The coagulation profile of cold-stored platelets was better maintained throughout storage compared to RT platelets. Cold-stored platelets showed increased thrombin generation potential (faster lag time, higher peak, and increased ETP) compared to RT platelets throughout storage. By viscoelastic testing, the IN-test and EX-test clotting times (CT) were maintained over cold storage for 21 days, while the clot strength (MCF) decreased by approximately 15%. The lysis time (LT) was unchanged during cold storage. Macroscopically, less clot retraction and a higher percentage of internal lysis were observed in cold-stored platelets; however, susceptibility to external lysis was not affected.</p><p><strong>Conclusion: </strong>Hemostasis requires a delicate balance between clot formation and resolution, and we have shown that the key functional properties of cold platelets stored in PAS-E are well-regulated during extended storage for 21 days.</p>","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144080641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A prospective non-inferiority trial of pathogen reduced platelets compared to non-pathogen reduced platelets for correction of viscoelastic platelet function testing in cardiac surgery.","authors":"Magali J Fontaine, Jackline J M Lasola, Aidaelis Martinez-Hernandez, Juliana N Marshall, Soren Bentzen, Min Zhan, Parvez M Lokhandwala, Kenichi Tanaka, Carlos H Villa, Alexis Jones, Chintamani D Atreya, Reney A Henderson","doi":"10.1111/trf.18281","DOIUrl":"https://doi.org/10.1111/trf.18281","url":null,"abstract":"<p><strong>Background: </strong>Cardiac surgery on cardiopulmonary bypass (CPB) may alter platelet (PLT) function causing bleeding. The goal of this study is to evaluate the hemostatic effect of PRT-PLTs compared to untreated PLTs stored in platelet additive solution (PAS) following transfusion in bleeding patients undergoing cardiac surgery on CPB.</p><p><strong>Methods: </strong>In this single-center, prospective single-blinded two-arm noninferiority trial, patients being weaned off CPB were allocated to either a PRT-PLT or a standard PAS-PLT. The primary outcome was the change in maximum amplitude (ΔMA) on thromboelastographic testing (TEG) from pre- to post-transfusion. The non-inferiority margin was chosen as 50% of the ΔMA observed with PAS-PLT using a 1-sided 95% confidence interval. The secondary outcomes included the volume of chest tube drainage (CTD) and the number of blood products transfused during the first 24 h post-surgery.</p><p><strong>Results: </strong>A modified intention-to-treat analysis included 90 patients (48 PRT-PLTs; 42 PAS-PLTs). The ΔMA for PRT-PLT was 2.93 mm (95% CI 1.52-4.34) and was lower than that achieved with PAS-PLT at 5.68 mm (95% CI 3.26-8.09) (2-tailed p = .052). The ratio of ΔMA for PRT-PLT relative to PAS-PLT was estimated at .52 with a 90% confidence interval (.29, .89) and did not meet the non-inferiority criterion (>.5). The CTD and the number of blood products transfused during the first 24 h post-surgery were similar in both arms.</p><p><strong>Conclusion: </strong>PRT-PLT transfusion results in lower responses in viscoelastic testing compared to PAS-PLT, although clinical outcomes with respect to blood component utilization and chest tube drainage were similar.</p>","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144080639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differences in the product characteristics and clinical use of granulocytes for transfusion: The BEST Collaborative study.","authors":"Lorna Cain, Charles Lafrance, Suzy Morton, Catherine Latour, Mélissa Girard, Pierre Tiberghien, Virginie de la Taille, Suvro Sankha Datta, Mrigender Singh Virk, Jennifer Andrews, Vered Yahalom, Ana María Pugliese, Romina Alba, Richard Charlewood, Susy Kirwan, Ana Paula Hitomi Yokoyama, Jose Mauro Kutner, Eva Alonso Nogues, Nuria Martinez I Llonch, James Daly, David O Irving, Torsten J Schulze, Elise Huisman, Kaatje Le Poole, Hans Vrielink, Nabiha H Saifee, Monica B Pagano, Simon Stanworth","doi":"10.1111/trf.18263","DOIUrl":"https://doi.org/10.1111/trf.18263","url":null,"abstract":"<p><strong>Background: </strong>Whether granulocytes for transfusion are beneficial remains uncertain, although some evidence suggests that efficacy may be dose-related. Granulocytes are mostly produced by apheresis procedure, but other means of production are increasingly used.</p><p><strong>Methods: </strong>Centers that produce and/or use granulocytes were recruited through the BEST Collaborative and completed a detailed survey of granulocyte manufacture, specifications, clinical use, operational considerations, and data collection initiatives.</p><p><strong>Results: </strong>Fifteen national, regional, and local producers and/or users of granulocytes were included. Granulocytes were produced from apheresis procedure (n = 10), pooled buffy coats (n = 2), single buffy coats (n = 4) or pooling of residual leukocyte units from whole blood processing (n = 1). The mean adult dose of granulocytes reported was 1.6 to 3.7 × 10¹⁰ for apheresis, and 1.8 to 2.2 × 10¹⁰ for pooled buffy coat granulocytes. For apheresis procedure donations, donor stimulation included steroids and/or granulocyte colony-stimulating factor. Centers providing whole blood-derived granulocytes reported shorter times from request to delivery than those using apheresis procedure products. Indications and product selection criteria were similar. The most frequently reported challenges with granulocytes were donor availability for apheresis procedure (n = 7), short shelf life (n = 5) and lack of evidence of efficacy (n = 5). The cost of one unit of apheresis procedure granulocytes ranged from 568 to 7500 PPP-USD, and for one pooled buffy coat unit was from 2208 to 2822 PPP-USD.</p><p><strong>Conclusions: </strong>We have highlighted differences in granulocyte production that are relevant for the design and interpretation of much needed international clinical studies.</p>","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144080643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gelofusine as alternative to Dextran40-based solution for washing cryopreserved hematopoietic stem cell products prior to infusion: Validation and application to clinical practice.","authors":"Stefania Nappo, Mario Toriello, Giovanna Maisto, Peppino Mirabelli, Francesco Topo, Lucia Gallo, Giovanni Castellano, Martina Esposito, Laura Auriemma, Donato Madalese, Fabiana Cacace, Alessandra Picardi, Francesco Paolo Tambaro, Roberta Penta de Vera d'Aragona","doi":"10.1111/trf.18272","DOIUrl":"https://doi.org/10.1111/trf.18272","url":null,"abstract":"<p><strong>Background: </strong>Cryopreservation is an essential step for autologous hematopoietic stem cell (HSC) transplantation and umbilical cord blood units (CBUs), and for allogeneic peripheral blood stem cells (PBSCs) or bone marrow (BM) when immediate infusion is not possible. However, the cryoprotectant dimethyl sulfoxide (DMSO) used for HSC cryopreservation can be toxic to cells post-thaw and to patients during infusion. The Rubinstein solution is validated to wash HSCs, but the unavailability of Dextran40 in Italy prompted a search for alternatives. This report discusses the use of Gelofusine, a 4% modified gelatin solution, as a substitute for Dextran40-based solutions in washing cryopreserved stem cell products.</p><p><strong>Study design and methods: </strong>The study includes: (1) validation of Gelofusine in 10 CBUs unsuitable for transplantation; (2) outcomes of the first 93 transplanted units washed with Gelofusine; (3) comparisons of recovery and viability in five paired autologous PBSC products washed with Gelofusine and Rubinstein-solution; and (4) comparisons of engraftment times in patients receiving units washed with Gelofusine and Rubinstein-solution.</p><p><strong>Results and discussion: </strong>For 10 CBUs washed with Gelofusine, CD34⁺ and TNC viability and recovery were 96%, 87%, 71%, and 75% respectively, higher than our reference values. In transplanted products, CD34⁺ and TNC viability and recovery were 96%, 89%, 82%, and 91% respectively. Comparisons with Rubinstein solution revealed similar TNC and CD34⁺ recovery but significantly higher TNC (89% vs. 68%) and CD34⁺ (97% vs. 89%) viability with Gelofusine. Engraftment times for both solutions were similar. These findings support Gelofusine as an effective and valid alternative to Rubinstein-solution for washing cryopreserved HSCs.</p>","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144049666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vesiculation as potential novel pathogenic mechanism in autoimmune hemolytic anemia.","authors":"Esther C W de Boer, Femke V M Mulder, Silvia Neri, Marije Wiskerke-van Stuijvenberg, Janine J G Arts, Simon Tol, Boukje Beuger, Matthieu C J Bosman, Noortje Thielen, René van der Griend, Claudia C Folman, Masja de Haas, Robin van Bruggen, Richard B Pouw, Josephine M I Vos","doi":"10.1111/trf.18270","DOIUrl":"https://doi.org/10.1111/trf.18270","url":null,"abstract":"<p><strong>Background: </strong>Autoimmune hemolytic anemia (AIHA) is typically mediated by immunoglobulin G (IgG) or immunoglobulin M (IgM) antibodies, and more rarely by immunoglobulin A (IgA). The mechanism of red blood cell (RBC) destruction in IgA-mediated AIHA is not well understood. We report a case of severe AIHA with intravascular hemolysis, positive for IgA. Hemolysis did not subside despite multiple transfusions and treatment lines, leading to a fatal outcome. Here, we set out to investigate underlying pathophysiological mechanisms.</p><p><strong>Study design and methods: </strong>To investigate the underlying pathophysiological methods, standard hematological methods were used, as well as erythrophagocytosis assays and flow cytometry using patient RBCs and plasma, to investigate anti-RBC antibodies, complement activation, and vesiculation.</p><p><strong>Results: </strong>Blood smear analysis revealed significant heterogeneity in RBC size and volume, and the presence of ghost cells, indicating RBC damage. While the patient's RBCs were found opsonized with IgA and IgG autoantibodies, phagocytosis by neutrophils was not induced in vitro, nor did sensitized donor RBCs with patient plasma. Using flow cytometry, we detected vesicles in the patient's plasma and observed patient plasma-induced vesiculation of healthy donor RBC. Patient plasma showed marked complement activation, and the vesicles in the patient plasma were also complement-opsonized, as well as bound by IgA, IgG, and IgM.</p><p><strong>Conclusions: </strong>Based on these findings, we suggest vesiculation of RBCs as evidenced by the presence of vesicles and ghost cells in the patient, and subsequent complement activation induced by the vesicles. This could have driven the aggravation of the disease in this patient, resulting in a fatal outcome.</p>","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144033855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Massive transfusion on the combat field using autonomous drones: A case report.","authors":"Baki Türkoğlu, Mustafa Girayhan Ünlü, Murat Çamur, Ali Kağan Coşkun, Aytekin Ünlü","doi":"10.1111/trf.18279","DOIUrl":"https://doi.org/10.1111/trf.18279","url":null,"abstract":"<p><strong>Background: </strong>Hemorrhage is a leading cause of preventable deaths in combat settings, requiring rapid blood transfusion to improve survival. While the feasibility of drone-assisted medical logistics has been explored, its practical application in battlefield transfusion remains unreported.</p><p><strong>Study design and methods: </strong>This case report describes the first documented massive transfusion in a combat environment using an autonomous unmanned aerial vehicle (UAV). A 27-year-old soldier sustained severe lower limb injuries from an improvised explosive device explosion and developed hemorrhagic shock in a remote battlefield location where adverse weather conditions prevented immediate evacuation. In response, 6 units of whole blood and 2 units of fresh frozen plasma were transported via UAV, enabling prehospital transfusion under telemedicine supervision.</p><p><strong>Results: </strong>The UAV successfully delivered blood products on two consecutive flights, ensuring early resuscitation and stabilization despite delayed evacuation. The casualty's vital signs improved post-transfusion, and surgical interventions were successfully performed following hospital admission. This case demonstrates the feasibility of drone-assisted blood product transport in prolonged field care scenarios.</p><p><strong>Discussion: </strong>To our knowledge, this is the first reported case of a combat casualty receiving a UAV-facilitated massive transfusion in an operational setting. While UAV-based medical logistics offers a rapid and reliable alternative for remote trauma care, challenges remain in regulatory implementation, blood product stability, and integration into standardized protocols. Further controlled studies are needed to optimize UAV-assisted transfusion strategies and their potential expansion into civilian and disaster response settings.</p>","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143983422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Donating blood in a team: Investigating social factors as predictors and outcomes of a positive team experience.","authors":"Kristen S Baker, Kathleen Chell, Barbara M Masser, Marijke Welvaert","doi":"10.1111/trf.18271","DOIUrl":"https://doi.org/10.1111/trf.18271","url":null,"abstract":"<p><strong>Background: </strong>Social connections are crucial in blood donation, with positive social influences providing valuable information and serving as motivation to donate. Australian Red Cross Lifeblood's group donation program, Lifeblood Teams, leverages social connections by enabling donors to donate together and/or contribute to their team's donation tally. One-third of annual donations are from Team donors, yet predictors and outcomes of a positive team experience remain unexplored. This study investigated how connectedness and perceived benefits to being in a team influence team satisfaction, team identity, and advocacy for others to join a team and whether these relationships differ for novice and experienced donors.</p><p><strong>Study design and methods: </strong>Team registrants (n = 646) completed a survey on their team donation experiences linked to donor records. The survey investigated themes of motivations, rewards, and social factors to understand why donors join and continue donating with teams.</p><p><strong>Results: </strong>Feeling connected to team members and perceiving a greater number of benefits were positively related to higher team satisfaction, in turn leading to a stronger team identity and increased advocacy for others to join a team. The relationship between satisfaction with their team and advocating for others to join a team was stronger for novice than for experienced donors.</p><p><strong>Discussion: </strong>Blood collection agencies should promote team benefits and facilitate strengthening social ties within donation teams to ensure satisfying group donation experiences that lead to stronger team identities and increased advocacy for joining donation teams.</p>","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144039671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What have all the models done?","authors":"Aaron Stansbury Hess","doi":"10.1111/trf.18273","DOIUrl":"https://doi.org/10.1111/trf.18273","url":null,"abstract":"","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143983004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Estimating the incidence of transfusion-associated circulatory overload using active surveillance: A systematic review and meta-analysis.","authors":"Sandra K White, Brandon S Walker, Scott Potter, David Anderson, Ryan A Metcalf","doi":"10.1111/trf.18258","DOIUrl":"https://doi.org/10.1111/trf.18258","url":null,"abstract":"<p><strong>Background: </strong>Transfusion-associated circulatory overload (TACO) is an adverse event that is the leading cause of transfusion-related death. It is underrecognized, and the aim of this study was to synthesize the available evidence from active surveillance studies to estimate its incidence.</p><p><strong>Study design and methods: </strong>This study is a systematic review and meta-analysis of publications reporting TACO incidence using active surveillance. A research librarian searched Medline and Embase, identifying publications between January 1991 and June 2024. Studies reporting TACO either by patient, blood component (red blood cells [RBCs], platelets, or plasma) or transfusion episode were identified, and all patient settings were eligible. A random effects model estimated TACO incidence, and potential sources of heterogeneity were evaluated using meta-regression.</p><p><strong>Results: </strong>Twenty-two studies met eligibility criteria and were included for analysis. The rate per patient was 22.2/1000 (95% CI: 16.2-29.2) based on 21 studies. The rate estimate of TACO among total blood components (RBCs, plasma, and platelets combined) reported in 10 studies was 2.2/1000 units transfused (95% CI: 1.2-3.5/1000). There was substantial between-study variation in rates and more recent studies tended to report higher rates. Although the platelet point estimate was higher than the point estimates for RBCs and plasma, the confidence intervals overlapped. Only two studies reported TACO rates per transfusion episode and the pooled estimate was 6.3/1000 (95% CI: 1-16.3/1000), about three times greater than the overall per unit estimate.</p><p><strong>Discussion: </strong>Clinicians should consider quantitative risks of important transfusion-related harms, such as TACO, when making the decision to transfuse.</p>","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144049629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Performance of a whole blood immunoassay for tenofovir detection and correlation with self-reported pre-exposure prophylaxis use in HIV-negative men who have sex with men interested in blood donation.","authors":"Renata Buccheri, Barbee Whitaker, Lance M Pollack, Jahnavi Reddy Bhaskar, Clara Di Germanio, Geraldine Guillon, Richard Haaland, Susan L Stramer, Rita Reik, Suchitra Pandey, Mars Stone, Steven A Anderson, Peter Marks, Brian Custer","doi":"10.1111/trf.18275","DOIUrl":"https://doi.org/10.1111/trf.18275","url":null,"abstract":"<p><strong>Background: </strong>In 2023, the United States Food and Drug Administration revised its blood donor eligibility policy for men who have sex with men (MSM) from a 3-month deferral to individual assessment. Human Immunodeficiency Virus (HIV) pre-exposure prophylaxis (PrEP) use remains a reason for deferral, and nondisclosure is a concern.</p><p><strong>Study design and methods: </strong>In a cross-sectional study of sexually active MSM from 8 U.S. cities who were interested in future blood donation, we assessed the performance of an enzyme-linked immunosorbent assay for detecting tenofovir (TFV) in whole blood (WB) and plasma and the correlation with self-reported PrEP use.</p><p><strong>Results: </strong>Of 1548 individuals, 48% reported oral PrEP use. The WB assay identified 95% of PrEP users, while the plasma assay detected 88%. The WB assay performed well up to 14 days after the last reported dose. Receiver operating characteristics curve analysis showed an area under the curve of 0.96 (95% confidence interval [CI]: 0.95-0.97) using WB and 0.88 (95% CI: 0.86-0.90) using plasma. Specificity was 80% for WB and 66% for plasma. Detection rates for TFV disoproxil fumarate/emtricitabine (FTC) formulations were 99% in WB and 98% in plasma, compared to 93% and 86% for the TFV alafenamide/FTC formulation.</p><p><strong>Discussion: </strong>High concordance between self-reported oral PrEP use and TFV detection was observed among PrEP users, suggesting the potential utility of WB as a biomatrix for TFV detection to support screening strategies. Given the expanded eligibility for MSM, who may be PrEP users, to donate blood, further examination of undisclosed PrEP use is important.</p>","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144045384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}